Roth Capital Previews Preclinical PRESERVATION-1 Data; Affirms BioLineRx (BLRX) at 'Buy'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
- AMD shares fall amid AI chip sector selloff
- JetBlue shares fall amid American results, fuel cost concerns
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- LKQ posts Q3 loss, replaces CEO amid Europe struggles
UPDATE: JMP Securities Starts BioLineRx (BLRX) at Market Outperform
June 22, 2015 7:47 AM EDT(Updated - June 22, 2015 8:58 AM EDT)
JMP Securities initiated coverage on BioLineRx (NASDAQ: BLRX) with a Market Outperform rating and a price target of $5.00. Analyst Michael King Jr thinks investors are undervaluating the company's pipeline, given four of six assets are in phase II... More



